Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype, an International Phase II/Phase III, Randomized, Controlled Trial - TREAT-HAP Study.

NCT05914584 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT05914584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05914584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype, an International Phase II/Phase III, Randomized, Controlled Trial - TREAT-HAP Study.
Lead sponsor
Nantes University Hospital
Phase
Phase 2/3
Overall status
Unknown status
Start date
July 1, 2023
Completion date
December 31, 2025
Enrollment
450 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

hospital-acquired pneumonia